5213 related articles for article (PubMed ID: 15143768)
1. [The history of the development and changes of quinolone antibacterial agents].
Takahashi H; Hayakawa I; Akimoto T
Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
[TBL] [Abstract][Full Text] [Related]
2. [Phototoxicity studies of pazufloxacin mesilate, a novel parenteral quinolone antimicrobial agent--in vitro and in vivo studies].
Nagasawa M; Nakamura S; Miyazaki M; Nojima Y; Hayakawa H; Kawamura Y
Jpn J Antibiot; 2002 Jun; 55(3):259-69. PubMed ID: 12199110
[TBL] [Abstract][Full Text] [Related]
3. [Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
Nakamura T; Shimizu C; Hirakawa K; Inui S; Okuda K; Nakata C; Fujimoto H; Okura H; Uemura Y; Takahashi H
Jpn J Antibiot; 2009 Jun; 62(3):194-202. PubMed ID: 19882980
[TBL] [Abstract][Full Text] [Related]
4. [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Fukuda H; Kawamura Y
Jpn J Antibiot; 2002 Jun; 55(3):270-80. PubMed ID: 12199111
[TBL] [Abstract][Full Text] [Related]
5. [In vitro antibacterial activities of broad spectrum quinolones against clinical bacterial isolates].
Ishii Y; Ohno A; Yamaguchi K
Jpn J Antibiot; 1994 Jan; 47(1):22-8. PubMed ID: 8114270
[TBL] [Abstract][Full Text] [Related]
6. The fluoroquinolone antibacterials: past, present and future perspectives.
Appelbaum PC; Hunter PA
Int J Antimicrob Agents; 2000 Sep; 16(1):5-15. PubMed ID: 11185413
[TBL] [Abstract][Full Text] [Related]
7. [Alteration of antibacterial activity of tosufloxacin and various antibacterial agents against Streptococcus pneumoniae].
Maekawa M; Fukuda Y; Sugiura Y; Kamiyama T; Futakuchi N; Takahata M; Mitsuyama J
Jpn J Antibiot; 2003 Feb; 56(1):27-35. PubMed ID: 12723396
[TBL] [Abstract][Full Text] [Related]
8. In vitro antibacterial activity of FA103, a new quinolone derivative of C-7 position with 7-perhydrodiazepinone.
Imamori K; Asaoka T; Matsumoto M; Maebashi K; Matsuda H; Tahara Y
Jpn J Antibiot; 1995 Dec; 48(12):1891-8. PubMed ID: 8587163
[TBL] [Abstract][Full Text] [Related]
9. [In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
Inoue M; Kuga A; Kaieda S; Hosaka M; Kitasato H; Sato Y; Okamoto R; Eda T; Hoshino K; Seto I
Jpn J Antibiot; 2000 Sep; 53(9):593-608. PubMed ID: 11214999
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antibacterial activity of quinolone-based compounds containing a coumarin moiety.
Emami S; Foroumadi A; Faramarzi MA; Samadi N
Arch Pharm (Weinheim); 2008 Jan; 341(1):42-8. PubMed ID: 18072241
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
Inagaki H; Miyauchi S; Miyauchi RN; Kawato HC; Ohki H; Matsuhashi N; Kawakami K; Takahashi H; Takemura M
J Med Chem; 2003 Mar; 46(6):1005-15. PubMed ID: 12620077
[TBL] [Abstract][Full Text] [Related]
12. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
[TBL] [Abstract][Full Text] [Related]
13. [In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
Araake M; Hara T; Watabe H; Nishino T
Jpn J Antibiot; 2002 Dec; 55(6):778-90. PubMed ID: 12621732
[TBL] [Abstract][Full Text] [Related]
14. In vitro properties of the newer quinolones.
Nakanishi N; Kojima T; Fujimoto T; Mitsuhashi S
Prog Drug Res; 1992; 38():19-28. PubMed ID: 1609115
[TBL] [Abstract][Full Text] [Related]
15. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.
Kocsis B; Domokos J; Szabo D
Ann Clin Microbiol Antimicrob; 2016 May; 15(1):34. PubMed ID: 27215369
[TBL] [Abstract][Full Text] [Related]
16. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
17. Development of the quinolones.
Andersson MI; MacGowan AP
J Antimicrob Chemother; 2003 May; 51 Suppl 1():1-11. PubMed ID: 12702698
[TBL] [Abstract][Full Text] [Related]
18. [Role of new quinolones in the treatment of mycobacteriosis].
Kekkaku; 2003 Sep; 78(9):601-4. PubMed ID: 14577348
[TBL] [Abstract][Full Text] [Related]
19. [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone].
Nomura N; Mitsuyama J; Furuta Y; Yamada H; Nakata M; Fukuda T; Yamada H; Takahata M; Minami S
Jpn J Antibiot; 2002 Aug; 55(4):412-39. PubMed ID: 12378871
[TBL] [Abstract][Full Text] [Related]
20. Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens.
Hu XE; Kim NK; Gray JL; Almstead JI; Seibel WL; Ledoussal B
J Med Chem; 2003 Aug; 46(17):3655-61. PubMed ID: 12904069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
